Chronic myeloid leukemia (CML) is a stem cell disease, in which the BCR/ABL oncoprotein
is considered essential for abnormal growth and accumulation of neoplastic cells. During the …

Chronic myeloid leukaemia (CML) is a myeloid neoplasm defined by the BCR/ABL
oncoprotein that is considered essential for leukaemogenesis and accumulation of …

Targeted therapies of chronic myeloid leukemia (CML) using tyrosine kinase inhibitors (TKI)
have profoundly changed the natural history of the disease with a major impact on survival …

It is not clear if absence of BCR-ABL transcripts—complete molecular response (CMR)—is
synonymous with, or required for, cure of chronic myeloid leukemia (CML). Some patients …

In contrast to adult medicine, specific scoring systems predicting the treatment response for
an individual pediatric patient (pt) with chronic myeloid leukemia (CML) have not yet been …

Previous experience in the treatment of chronic myeloid leukaemia (CML) has shown that
the achievement of clinical, morphological and cytogenetic remission does not indicate …

Patients with chronic myeloid leukemia (CML) who have achieved a complete molecular
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …

Introduction: The ultimate goal for CML management is risk stratification of the patients to
design the appropriate treatment approach. The Sokal, Euro and EUTOS risk scores were …

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75–90%
of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage …

In chronic myeloid leukemia (CML), BCR-ABL-mediated oncogenic signaling can be
successfully targeted with the BCRABL-inhibitors imatinib, nilotinib, and dasatinib leading to …